Researchers have concluded the global clinical trial of a new type of cancer drug that can penetrate tumour cells and attack them from within. The new drug is called Tisotumab Vedotin (TV) and the clinical trial was led by a team from the Institute of Cancer Research, London, and the Royal Marsden NHS Foundation Trust. A ‘Trojan Horse’ approach was employed in advanced, drug-resistant cancers and showed promising results in a small percentage of them.
The findings saw the tumours either shrink or stop growing in 27 per cent of patients with bladder cancer, 26.5 per cent of patients with cervical cancer, 14 per cent of ovarian cancer sufferers, 13 per cent of those with oesophageal cancer, 13 per cent of patients with non-small cell lung cancer, and seven per cent of those with endometrial cancer.
This might be the start of a novel arsenal against these types of diseases. The team is already looking at the next steps.
www.iflscience.com
